Want to see IN:HESTERBIO full AI Analyst Report?
Top Page
Hester Biosciences Limited
(HESTERBIO)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹2,746.00
▲(71.01% Upside)
Action:Reiterated
Date:07/14/26
The score is primarily supported by improving financial performance (profitability rebound and better leverage) and strong technical momentum with price above major moving averages. These positives are offset by a demanding valuation (high P/E and low yield) and lingering financial quality risks from historically volatile margins and uneven cash flow.
Positive Factors
Steady multi-year revenue growth and 2026 re-acceleration
Consistent multi-year revenue expansion and a clear 2026 re-acceleration indicate durable demand for veterinary vaccines and products. This supports predictable recurring sales, better capacity utilization and long-term scaling of manufacturing and distribution investments.
Negative Factors
Historic margin volatility and uneven earnings quality
Significant swings in gross and net margins reduce predictability of profitability and complicate financial planning. Persistent margin variability can undermine long-term margin sustainability, making capital allocation, pricing power and investor forecasting more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady multi-year revenue growth and 2026 re-acceleration
Consistent multi-year revenue expansion and a clear 2026 re-acceleration indicate durable demand for veterinary vaccines and products. This supports predictable recurring sales, better capacity utilization and long-term scaling of manufacturing and distribution investments.
Read all positive factors
Hester Biosciences Limited (HESTERBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹20.72B
Dividend Yield0.44%
Average Volume (3M)308.00
Price to Earnings (P/E)36.6
Beta (1Y)0.58
Revenue Growth6.91%
EPS Growth102.41%
CountryIN
Employees483
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)66.93
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hester Biosciences Limited Business Overview & Revenue Model
Company Description
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both ...
How the Company Makes Money
Hester Biosciences makes money primarily by selling animal healthcare products, with a strong emphasis on veterinary vaccines (veterinary biologicals). Revenue is generated from (1) domestic sales in India to poultry and livestock industry custome...
Hester Biosciences Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
62
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.33B | 3.11B | 3.05B | 2.66B | 2.35B |
| Gross Profit | 1.69B | 2.08B | 972.64M | 1.89B | 1.66B |
| EBITDA | 866.58M | 649.76M | 582.46M | 619.20M | 731.93M |
| Net Income | 556.39M | 274.88M | 188.89M | 266.27M | 393.20M |
Balance Sheet | |||||
| Total Assets | 6.78B | 6.53B | 6.62B | 6.70B | 5.62B |
| Cash, Cash Equivalents and Short-Term Investments | 65.38M | 72.19M | 153.04M | 148.17M | 252.20M |
| Total Debt | 1.95B | 2.13B | 2.44B | 2.74B | 2.28B |
| Total Liabilities | 3.10B | 3.27B | 3.59B | 3.81B | 2.95B |
| Stockholders Equity | 3.60B | 3.14B | 2.92B | 2.80B | 2.60B |
Cash Flow | |||||
| Free Cash Flow | 417.03M | 439.20M | 237.37M | -541.66M | -869.02M |
| Operating Cash Flow | 595.31M | 645.11M | 481.34M | 235.96M | 88.08M |
| Investing Cash Flow | -49.00M | -190.03M | -226.54M | -769.99M | -1.17B |
| Financing Cash Flow | -421.53M | -517.17M | -260.45M | 417.58M | 1.12B |
Hester Biosciences Limited Technical Analysis
Positive
1605.75
Price Trends
2009.55
Positive
1743.52
Positive
1683.72
Positive
Market Momentum
107.69
Negative
66.40
Neutral
58.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Positive. The current price of 1605.75 is below the 20-day moving average (MA) of 2203.40, below the 50-day MA of 2009.55, and below the 200-day MA of 1683.72, indicating a bullish trend. The MACD of 107.69 indicates Negative momentum. The RSI at 66.40 is Neutral, neither overbought nor oversold. The STOCH value of 58.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HESTERBIO.
Hester Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹20.72B | 36.57 | ― | 0.44% | 6.91% | 102.41% | |
58 Neutral | ₹33.32B | 34.05 | ― | 0.49% | -0.32% | -22.18% | |
57 Neutral | ₹42.60B | 16.40 | ― | ― | 8.53% | 67.93% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹38.90B | 59.67 | ― | 0.03% | 15.15% | -7.86% | |
43 Neutral | ₹23.28B | -23.04 | ― | 0.08% | 10.73% | -31.79% |
* General Sector Average
IN:HESTERBIO
Hester Biosciences Limited
2,445.15
526.66
27.45%
IN:GUFICBIO
Gufic Biosciences Limited
381.60
-1.60
-0.42%
IN:INDOCO
Indoco Remedies Limited
246.65
-76.67
-23.71%
IN:MOREPENLAB
Morepen Laboratories Limited
58.95
-3.35
-5.38%
IN:UNICHEMLAB
Unichem Laboratories Limited
589.95
-39.30
-6.25%
Hester Biosciences Limited Corporate Events
Hester Biosciences Discloses Resignation of Non-Executive Director Ravin Gandhi
May 12, 2026
Hester Biosciences Limited announced that non-executive director Ravin Gandhi has resigned from the board with effect from 12 May 2026, citing professional and personal commitments that prevent him from devoting sufficient time to company affairs....
Hester Biosciences Non-Executive Director Ravin Gandhi Resigns, Alternate Director Role Ends
May 12, 2026
Hester Biosciences has announced the resignation of non-executive director Ravin Gandhi, effective 12 May 2026, after he cited ongoing professional and personal commitments that prevent him from devoting sufficient time to board duties and company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.